Invivyd Inc
IVVD
Company Profile
Business description
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
Contact
209 Church Street
New HavenCT06510
USAT: +1 781 819-0080
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
122
Stocks News & Analysis
stocks
Samsung and SK Hynix lead chip selloff as China competition fears grow
CXMT’s claimed tech breakthrough and an AI industry leader’s comments are weighing on stocks across the sector.
stocks
Updating our assumed commodity prices and fair values of the two largest Aussie miners
Stronger copper, aluminum and zinc prices offset by iron ore.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,846.70 | 74.80 | -0.84% |
| CAC 40 | 7,827.63 | 5.25 | -0.07% |
| DAX 40 | 25,259.90 | 17.78 | -0.07% |
| Dow JONES (US) | 51,670.10 | 180.45 | -0.35% |
| FTSE 100 | 10,650.33 | 5.95 | -0.06% |
| HKSE | 24,290.46 | 54.76 | -0.22% |
| NASDAQ | 27,204.38 | 41.52 | -0.15% |
| Nikkei 225 | 68,142.40 | 364.88 | 0.54% |
| NZX 50 Index | 13,729.85 | 19.75 | -0.14% |
| S&P 500 | 7,805.45 | 1.79 | -0.02% |
| S&P/ASX 200 | 8,704.00 | 79.90 | -0.91% |
| SSE Composite Index | 3,804.72 | 3.85 | 0.10% |